HK Stock Market Move | LI AUTO (02015) rises by over 8%, the new Ideal L8 will officially launch on June 23rd.
Ideal car-W (02015) rose more than 8%, as of the time of issuance, it rose by 8%, to 57.4 Hong Kong dollars, with a turnover of 8.34 billion Hong Kong dollars.
LI AUTO-W(02015) rose more than 8%, as of the press release, it rose 8% to 57.4 Hong Kong dollars, with a turnover of 8.34 billion Hong Kong dollars.
On the news front, on June 12th, Li Auto announced that the new Li ONE L8 will officially launch on June 23rd, positioning itself as a "five-seater flagship SUV without any compromises." Western has recently pointed out that the company is in a product transition period, having cleared inventory of old models in the first quarter, with the L9 starting deliveries in May and the all-new L8 Livis expected to start deliveries at the end of June, with substantial upgrades in body size, power system, intelligent hardware, and seat layout. With the increase in delivery volume of L9 in the second quarter, the company expects the gross margin for Q2 to rebound to 10%.
Related Articles

William Li: Chinese car companies are transitioning from single-point competition to system competition.

New stock news | Meedu once again submits application to the Hong Kong Stock Exchange to develop and provide comprehensive technology-driven marketing, sales, and operational support services.

New Stock News | Lanna Cheng submits again to the Hong Kong Stock Exchange, dedicated to the discovery, development, and commercialization of radiopharmaceuticals for cancer diagnosis and treatment.
William Li: Chinese car companies are transitioning from single-point competition to system competition.

New stock news | Meedu once again submits application to the Hong Kong Stock Exchange to develop and provide comprehensive technology-driven marketing, sales, and operational support services.

New Stock News | Lanna Cheng submits again to the Hong Kong Stock Exchange, dedicated to the discovery, development, and commercialization of radiopharmaceuticals for cancer diagnosis and treatment.

RECOMMEND





